These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 28280302)

  • 1. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    Munroe M; Kolesar J
    Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
    N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
    J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC; Moore KN
    Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
    BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.